Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2019

View Archived Issues

CRISPR: Efficient editing and efficient inhibition

Gilead and Goldfinch Bio enter strategic collaboration to develop novel therapies for kidney disease

Imidazopyridines targeting methionyl-tRNA synthetase for the treatment of Cryptosporidium infection

Phase II results on ribaxamase to prevent C. difficile infection in beta-lactam-treated patients

New mouse model identifies MYC role in the tumorigenesis of group 3 medulloblastoma

First patient treated in phase I study MCLA-145 for the treatment of advanced solid tumors

Dosing begins in phase IIa PANASH study of liver stem cell therapy in late-stage NASH

CheckMate498 phase III study of Opdivo does not meet primary endpoint

resTORbio initiates phase III program of RTB-101 in clinically symptomatic respiratory illness

Nintedanib ophthalmic nanosuspension tested in animal model as pterygium treatment

First clinical results on K-0706 presented as potential treatment for Parkinson's disease

CAR T-cell therapy targeting AMHR2, a potential treatment for ovarian cancer

Bristol-Myers Squibb presents new hSTING agonists

Incyte patents PI3Kgamma inhibitors

Epizyme discloses EHMT1 and/or EHMT2 inhibitors

eFFECTOR Therapeutics describes MNK1 and MNK2 inhibitors

Tempest Therapeutics divulges IDO1 inhibitors

New phase I trial explores Precigen's PRGN-3005 UltraCAR-T cells for advanced ovarian cancer

Aptose begins phase Ia/Ib study of CG-806 in CLL, SLL and NHL

Mustang announces new phase I trial of CAR T-cell therapy for multiple myeloma

BioCryst completes phase I study of intravenous galidesivir in healthy subjects

Pooled safety analyses of global roxadustat phase III program confirm CV safety

Liver chats with fat via serum protein GPNMB

Urinary NT-proBNP a pulmonary hypertension marker in preterm infants with bronchopulmonary dysplasia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...